Pyridoimidazolyl Sulfonamide Compound 2: Pharmacological Data for a Gout Drug Candidate

A medicinal chemistry dataset from figshare, authored by Xiaoyu Shi and last updated in May 2026. It details the synthesis and evaluation of 40 novel sulfonamide derivatives as potential dual-acting drugs for gout. The lead compound demonstrated potent URAT1 inhibition and anti-inflammatory activity in preclinical mouse and rat models.

Use Cases

• Modeling structure-activity relationships based on the synthesis of 40 novel derivatives.
• Predicting in vivo efficacy for uric acid reduction based on IC50 values and animal model results.
• Analyzing pharmacokinetic properties like half-life and oral bioavailability for drug candidate optimization.
• Investigating dual-action therapeutic mechanisms by correlating URAT1 inhibition with IL-1β activity suppression.

Strengths

• Includes specific, quantitative pharmacological metrics such as IC50 values (0.19 μM for URAT1, 3.39 μM for IL-1β).
• Reports in vivo efficacy results from two animal models (mice and rats) with high serum uric acid reduction percentages (96.8% and 91.9%).
• Provides key pharmacokinetic and safety data, including half-life (6.3 h), oral bioavailability (20.1%), and maximum tolerated dose (>1000 mg/kg).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (266.4 KB), indicating a limited scope focused on a specific compound series.

Provenance

Source

figshare, author Xiaoyu Shi.

Collection Method

Likely contains experimental results from the synthesis and pharmacological testing of chemical compounds.

Freshness

Last updated 2026-05-26 21:06:27; freshness should be verified.